Organogenesis swings to Q3 net loss of $29.63 million from year-earlier profit
ORGO•Organogenesis reported a third-quarter 2026 net loss of $29.63 million, compared with net income of $21.57 million a year earlier. Net product revenue fell 70% to $45.46 million, and the company expects FY26 net revenue of $179.4 million to $200 million.
1. Quarterly results
Organogenesis swung to a third-quarter 2026 net loss of $29.63 million from net income of $21.57 million a year earlier. Net product revenue declined 70% year over year to $45.46 million, driven by lower Advanced Wound Care sales.
2. Cash and outlook
Cash, cash equivalents and restricted cash totaled $26.9 million at September 30, 2026, with no outstanding debt obligations. The company now expects FY26 net revenue of $179.4 million to $200 million, a 65% to 68% decline from the prior year.
